IDH1 and acute myeloid leukemia: Clinically, ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) induce meaningful remissions in relapsed/refractory (R/R) AML, with response rates of ∼30–40% (Stein et al., 2017).